Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
Date:11/9/2010

ons in post-meal glucose increases with APD597 alone and in combination with sitagliptin, a DPP-4 inhibitor.
  • Announced results from a Phase 1 clinical trial of APD916, a novel drug candidate Arena discovered that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy. In this randomized, double-blind, placebo-controlled trial in 24 healthy volunteers, APD916 demonstrated dose-proportional pharmacokinetic exposure over the tested dose range.
  • Received gross proceeds of approximately $60.0 million from the sale of 8,955,224 shares of its common stock to certain Deerfield entities at a price of $6.70 per share. As part of the transaction, Arena amended its June 2009 Facility Agreement with Deerfield pursuant to which $30.0 million of the proceeds from this transaction was used to prepay the portion of the principal amount that Arena otherwise would have been required to repay in July 2012.

  • Conference Call & Webcast Arena will host both a conference call and webcast to discuss top-line results from the BLOOM-DM trial and third quarter 2010 financial results today, November 9, 2010, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Jack Lief, President and Chief Executive Officer, and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer, will host the conference call.

    The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Third Quarter 2010" conference call. The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be neces
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
    2. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
    3. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
    4. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
    5. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
    6. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
    7. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
    8. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
    9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
    10. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
    11. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... IRVINE, Calif. , Aug. 31, 2015 /PRNewswire/ ... business and government, where regulations are often strict ... environment is driving a demand for professionals who ... interpret these regulations across a product lifecycle and ... organization. The University of California, Irvine Extension ...
    (Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
    (Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
    Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
    ... 2011 Reportlinker.com announces that a new market research ... Global Injectable Drug Delivery Market (2010 - 2015) ... KEY TAKE AWAYS * To ... its various sub-segments with respect to types of systems, ...
    ... Reportlinker.com announces that a new market research report ... European Markets for Minimally Invasive Spinal Devices ... The European minimally invasive spinal implant ... Rapid growth of the MIS interbody and MIS ...
    Cached Medicine Technology:Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 2Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 3Reportlinker Adds European Markets for Minimally Invasive Spinal Devices 2011 2
    (Date:9/1/2015)... ... 2015 , ... A new episode of “Voices In America”, hosted by famous ... topic of arthritis. There are over 100 different types of arthritis. One of the ... in an effort to shed light on this important topic. , Anyone who is ...
    (Date:9/1/2015)... ... , ... The premier online medical education company for Podiatrists ... podiatric, surgical and wound care conferences . The Residency Education Summits standardize ... the podium and across the table during hands-on surgical and advanced wound care ...
    (Date:8/31/2015)... Orange, NJ (PRWEB) , ... September 01, 2015 ... ... the spine to eliminate chronic back pain – once required a long, arduous ... a shorter hospital stay, less pain, less blood loss and minimal muscle damage. ...
    (Date:8/31/2015)... ... August 31, 2015 , ... ITC ... wealth of information for specific translation services within the medical and pharmaceutical industries. ... track record of successful work. , ITC Global Translations specializes in professional translation ...
    (Date:8/31/2015)... ... , ... In an article based on a reader’s question that ... of treating back pain caused by a disrupted disk by using steroids rather than ... function in patients suffering from a herniated disk, the level of pain that patients ...
    Breaking Medicine News(10 mins):Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2
    ... and Rainbow,Kitchen Community Services announced today that they ... Against Hunger" on Saturday, April 26, 2008.,The event ... and services, and raises public awareness about the,benefits ... participants can either walk or ride bicycles,along the ...
    ... April 24 Prime Therapeutics (Prime), a,thought leader ... RPh, has joined the organization as Vice President ... Pharmacy Trade Relations, Wan will focus on,developing and ... Prime,s efforts in the development of strategic pharmacy,contracts ...
    ... Frankfurt: I7VF), INVERNESS, Scotland, April 24 /PRNewswire-FirstCall/ - ... sheet restructuring,leaving it free of all loan note indebtedness, ... to enable it to move forward. The Company has,been ... 2005., Medical Diagnostic Innovations Ltd, a UK investment ...
    ... (Nasdaq: STAA ) today announced that it will ... 2008 on Tuesday, May 6, 2008,after the market close. ... Tuesday, May 6, 2008 at 5:00 p.m. Eastern Time ... The dial-in number for,the conference call is 866-250-3615 for ...
    ... 24 The Quigley,Corporation (Nasdaq: QGLY ) today ... the first quarter ended March 31, 2008,compared to $6.1 ... The first quarter of 2008 reflects a net sales ... compared to the first quarter,of 2007. The change during ...
    ... ) announced that it will release first quarter 2008,financial results on Thursday, ... The Company will host a conference call to discuss the first ... First Quarter 2008 Earnings Conference Call, ... Thursday, May 1, 2008 at 5:00 p.m. Eastern Time, Dial-in: ...
    Cached Medicine News:Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 2Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 3Health News:IVMD Inc. Announces Fundamental Balance Sheet Restructuring. 2Health News:IVMD Inc. Announces Fundamental Balance Sheet Restructuring. 3Health News:STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 3Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 4Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 5
    ... to 350 Liters of pure water, Complete, ... of Purified Water,Millipores compact S.D.S. Storage and ... to 350 liters of purified water produced ... maintain consistent purity of stored water, provide ...
    ... to 350 Liters of pure water, Complete, ... of Purified Water,Millipores compact S.D.S. Storage and ... to 350 liters of purified water produced ... maintain consistent purity of stored water, provide ...
    ... 350 Liters of pure water, Complete, Compact ... Purified Water,Millipores compact S.D.S. Storage and Distribution ... 350 liters of purified water produced by ... consistent purity of stored water, provide effective ...
    ... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
    Medicine Products: